MarketPeel
Insider Trading Intelligence
Pricing
…
WR

William E. Rote

TVTX
CHIEF RESEARCH OFFICER · TRAVERE THERAPEUTICS, INC. · CIK 0001698262
FILING MIX · LIFETIME43%/57%
BUYS
27
SELLS
36
TOTAL VALUE
$5.89M
COMPANIES
1
ACTIVE SINCE
Jan 2021
HOLDINGS NOW
115,474
AVG SELL PX
$31.34
TRADE KIND
SHOWING 63 / 63
Trades · vs SPY
Loading price series…
Performance · forward returns vs SPY
18 backtested trades · 8 horizons · 16 pending
Forward-return performance of every backtestable P/S trade by William E. Rote, measured at 8 horizons from 7 days to 2 years. Deduped per economic event so co-filings count once. Excess return = trade return minus SPY return over the same window.
HORIZONTRADESWIN RATEINSIDER RETURNSPY RETURNMEAN EXCESSMEDIAN EXCESST-STAT
7d18+50.00%+0.18%+0.29%-0.11%-2.24%—
14d18+66.67%-5.09%+0.33%-5.43%-7.73%—
30d18+66.67%-7.77%+0.84%-9.56%-8.24%—
60d18(1 pending)+70.59%-8.01%+2.05%-10.05%-20.64%—
90d18(2 pending)+68.75%-9.47%+3.82%-13.29%-28.82%—
180d18(3 pending)+53.33%+4.12%+7.77%-3.65%-2.33%—
1y18(4 pending)+50.00%+17.47%+11.27%+6.20%+0.30%—
2y18(6 pending)+75.00%+12.04%+23.34%-11.30%-37.60%—
How to read this: Insider Returnis the average raw return of the filer's trades over the horizon. SPY Return is what SPY did over those same windows — reference only, not a comparison. The headline alpha number is Mean Excess = Insider − SPY; green means the filer beat SPY, red means they trailed it. Win rate is the share of individual trades where the filer beat SPY. T-statvalues above 2 mean the alpha is unlikely to be chance given the sample size. "Pending" counts trades where the horizon hasn't elapsed yet; their stats are not included in the row average.
Holdings over time
TVTX · 115,474 shares · as of May 6, 2026
040,36180,722121,082161,44320222023202420252026SHARES HELD
Trading cadence · quarterly flow
BUY ● SELL ●
2021
2021
2021
2021
2022
2022
2022
2022
2023
2023
2023
2023
2024
2024
2024
2024
2025
2025
2025
2025
2026
2026
FLOW · 27 buys / 36 sellsCOVERAGE · 22 quarters
Form 4 filings · all activity
COMPANYTYPESHARESPRICEVALUEHELD AFTERTRADE DATEFILEDDETAILS
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,763$43.95$121.4K115,474May 6, 2026May 6, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Research Officer
4,250——4,250May 4, 2026May 6, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,500——8,500May 4, 2026May 6, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
Chief Research Officer
4,250——118,237May 4, 2026May 6, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
9,100$39.09$355.7K113,987Apr 22, 2026Apr 23, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
14,000——123,087Apr 13, 2026Apr 15, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
12,446$32.87$409.1K109,087Feb 3, 2026Feb 3, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,090——121,533Jan 31, 2026Feb 3, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
53,570——53,570Jan 31, 2026Feb 3, 2026 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
60,000$40.10$2.41M101,443Dec 24, 2025Dec 29, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
Chief Research Officer
60,000$20.61$1.24M161,443Dec 24, 2025Dec 29, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Research Officer
60,000——0Dec 24, 2025Dec 29, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
3,198$21.05$67.3K100,241May 5, 2025May 5, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Chief Research Officer
4,920——4,920May 2, 2025May 5, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
Chief Research Officer
4,920——103,439May 2, 2025May 5, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
5,200$23.53$122.4K98,519Feb 12, 2025Feb 12, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASE
SENIOR VICE PRESIDENT, R&D
8,000——103,719Feb 10, 2025Feb 12, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
SENIOR VICE PRESIDENT, R&D
8,000——0Feb 10, 2025Feb 12, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
8,951$19.78$177.1K95,719Feb 3, 2025Feb 4, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
58,000——58,000Jan 31, 2025Feb 4, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
21,500——104,670Jan 31, 2025Feb 4, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
2,437$19.46$47.4K83,170Jan 22, 2025Jan 23, 2025 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
4,387$11.52$50.5K84,455Sep 9, 2024Sep 9, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,750——88,842Sep 5, 2024Sep 9, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
SENIOR VICE PRESIDENT, R&D
2,174$8.53$18.5K83,310Feb 1, 2024Feb 2, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
SENIOR VICE PRESIDENT, R&D
2,590$8.86$22.9K80,720Feb 1, 2024Feb 2, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
65,000——65,000Jan 31, 2024Feb 2, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
25,000——85,484Jan 31, 2024Feb 2, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
SENIOR VICE PRESIDENT, R&D
2,062$8.96$18.5K60,484Jan 23, 2024Jan 25, 2024 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
1,815$14.71$26.7K61,173Sep 5, 2023Sep 5, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
3,300——62,988Aug 31, 2023Sep 5, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE10b5-1
10b5-1 plan
825$16.59$13.7K59,211May 10, 2023May 12, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
2,590$22.25$57.6K60,036Feb 1, 2023Feb 2, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
6,750——6,750Jan 31, 2023Feb 2, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
20,250——62,626Jan 31, 2023Feb 2, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
54,500——54,500Jan 31, 2023Feb 2, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
2,062$21.50$44.3K42,376Jan 24, 2023Jan 26, 2023 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
750$21.93$16.4K44,485May 11, 2022May 12, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
813$21.52$17.5K43,672May 11, 2022May 12, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,840——46,360Jan 31, 2022Feb 2, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
9,840——9,840Jan 31, 2022Feb 2, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
1,125$27.40$30.8K45,235Jan 31, 2022Feb 2, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
39,360——39,360Jan 31, 2022Feb 2, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
8,000——8,000Jan 31, 2022Feb 2, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
1,875$24.98$46.8K36,520Jan 24, 2022Jan 26, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
2,500$27.40$68.5K38,395Jan 11, 2022Jan 12, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,000——40,895Jan 10, 2022Jan 12, 2022 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
1,407$17.12$24.1K35,731Aug 17, 2021Aug 17, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,500——37,138Aug 13, 2021Aug 17, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
1,562$19.46$30.4K31,707May 12, 2021May 13, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
1,563$19.14$29.9K33,269May 11, 2021May 13, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
1,250$28.67$35.8K34,832Feb 18, 2021Feb 18, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
1,250$27.35$34.2K36,082Feb 17, 2021Feb 18, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
2,250$31.58$71.1K37,332Feb 8, 2021Feb 9, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
2,250$31.41$70.7K39,582Feb 5, 2021Feb 9, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
1,125$28.91$32.5K37,332Feb 3, 2021Feb 3, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
2,500$28.91$72.3K38,457Feb 3, 2021Feb 3, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
4,500——41,832Feb 3, 2021Feb 5, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
2,500$30.75$76.9K40,957Feb 2, 2021Feb 2, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
SALE
Senior Vice President, R&D
1,125$30.75$34.6K43,457Feb 2, 2021Feb 2, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
5,000——44,582Jan 31, 2021Feb 2, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
15,000——39,582Jan 21, 2021Jan 25, 2021 ↗View →
TVTX
TRAVERE THERAPEUTICS, INC.
PURCHASEGRANT
Stock grant
57,500——57,500Jan 21, 2021Jan 25, 2021 ↗View →
Other insiders · TVTX
Loading peer insiders…
About this filer
CIK 0001698262
ROLE
Chief Research Officer
PRIMARY
TVTX
COMPANIES
1
ACTIVE SINCE
Jan 2021
MARKETPEEL · /INSIDER/0001698262DATA · SEC EDGAR · FORM 4 · CONSOLIDATED TAPE
FREE · DAILY · 6 AM ET

The morning brief, before the bell.

One short email. Insider buys, congressional trades, and plain-English analysis.

Feedback